Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirin

Clinical Chemistry

Volumn 59, Issue 8, 2013, Pages 1195-1204

  Li, Ruizhi ^a   Fries, Susanne ^b   Li, Xuanwen ^b   Grosser, Tilo ^b   Diamond, Scott L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; COLLAGEN; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; THROMBOXANE;

ARTERY WALL; HUMAN; HUMAN TISSUE; IC 50; MICROFLUIDIC ANALYSIS; PERFUSION; REVIEW; SHEAR RATE; SHEAR STRESS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; VEIN WALL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ASPIRIN; BLOOD PLATELETS; COLLAGEN; CYCLOOXYGENASE 1; FEMALE; FLUORESCENT DYES; HUMANS; MALE; MICROFLUIDIC ANALYTICAL TECHNIQUES; MIDDLE AGED; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; REFERENCE VALUES; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION; STRESS, MECHANICAL; THROMBOXANE A2; YOUNG ADULT;

EID: 84880886516     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.198101     Document Type: Review

References (24)

1. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness and side effects. Chest 2004; 126:234s-64s.
2. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease. JAMA 2007;297:2018-24.
3. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-8.
4. Michelson AD, Frelinger LA, Furman. MI. Resistance to antiplatelet drugs. Eur Heart J Supp 2006;8(Suppl G):G53-8.
5. Fries S, Grosser, T. The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program 2005;445-51.
6. Grosser T, Yu, Y, FitzGerald, G. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 2010;61:17-33.
7. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489-93.
8. Michelson AD, Canntaneo M, Ekielboom JW, Gur-bel PA, Kottke-Merchant K, Kunicki TJ, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309-11.
9. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 2004;43: 1127-9.
10. Cattaneo M. Aspirin and clopidogrel: efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-7.
11. Cuisset T, Frere C, Quilici J, Gaborit B, Bali L, Poyet R, Faille, D, et al. Aspirin noncompliance is the major cause of 'aspirin resistance' in patients undergoing coronary stenting. Am Heart J 2009; 157:889-93.
12. Schwatz KA, Schwatz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 2008;6:46.
13. Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg 60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994;94: 1662-7.
14. Flamm MH, Colace TV, Chatterjee MS, Jing H, Zhou S, Jaeger D, Brass LF, Sinno T, Diamond SL. Multiscale prediction of patient specific platelet function under flow. Blood 2012;120:190-8.
15. Frelinger A, Li Y, Linden M, Barnard M, Fox M, Christie, D, et al. Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirintreated patients presenting for cardiac catheterization. Circulation 2009;120:2586-96.
16. Reny J, Berdaque P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 2012;125:3201-10.
17. Chatterjee MS, Purvis, JE, Brass LF, Diamond SL. Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli. Nature Biotechnol 2010;28:727-32.
18. Maloney SF, Brass LF, Diamond SL. P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions. Integr Bio (Camb) 2010;2:183-92.
19. Colace TV, Muthard RW, Diamond SL. Thrombus growth and embolism on tissue factor-bearing collagen surface under flow: role of thrombin with and without fibrin. Arterioscler Thromb Vasc Biol 2012;32:1466-76.
20. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used antiinflammatory drugs. Am J Med 1998;104:413-21.
21. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 1993;82:505-12.
22. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28:1702-8.
23. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-17.
24. Stephens G, He M, Wong C, Jurek M, Luedemann HC, Shapurian G. Development of a perfusion chamber assay to study in real time the kinetics of thrombosis and the antithrombotic characteristics of antiplatelet drugs. Thrombosis J 2012;10: 1-11.